HALO
Price
$77.91
Change
+$1.43 (+1.87%)
Updated
Feb 4, 04:59 PM (EDT)
Capitalization
8.99B
20 days until earnings call
Intraday BUY SELL Signals
RPRX
Price
$43.61
Change
+$0.64 (+1.49%)
Updated
Feb 4, 03:15 PM (EDT)
Capitalization
18.36B
7 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

HALO vs RPRX

Header iconHALO vs RPRX Comparison
Open Charts HALO vs RPRXBanner chart's image
Halozyme Therapeutics
Price$77.91
Change+$1.43 (+1.87%)
Volume$49.07K
Capitalization8.99B
Royalty Pharma
Price$43.61
Change+$0.64 (+1.49%)
Volume$4.25K
Capitalization18.36B
HALO vs RPRX Comparison Chart in %
HALO
Daily Signal:
Gain/Loss:
RPRX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
HALO vs. RPRX commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HALO is a StrongBuy and RPRX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (HALO: $76.48 vs. RPRX: $42.97)
Brand notoriety: HALO and RPRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HALO: 184% vs. RPRX: 85%
Market capitalization -- HALO: $8.99B vs. RPRX: $18.36B
HALO [@Biotechnology] is valued at $8.99B. RPRX’s [@Biotechnology] market capitalization is $18.36B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HALO’s FA Score shows that 1 FA rating(s) are green whileRPRX’s FA Score has 2 green FA rating(s).

  • HALO’s FA Score: 1 green, 4 red.
  • RPRX’s FA Score: 2 green, 3 red.
According to our system of comparison, both HALO and RPRX are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HALO’s TA Score shows that 5 TA indicator(s) are bullish while RPRX’s TA Score has 5 bullish TA indicator(s).

  • HALO’s TA Score: 5 bullish, 4 bearish.
  • RPRX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, HALO is a better buy in the short-term than RPRX.

Price Growth

HALO (@Biotechnology) experienced а +8.91% price change this week, while RPRX (@Biotechnology) price change was +5.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.56%. For the same industry, the average monthly price growth was +1.40%, and the average quarterly price growth was +33.10%.

Reported Earning Dates

HALO is expected to report earnings on Feb 24, 2026.

RPRX is expected to report earnings on Feb 11, 2026.

Industries' Descriptions

@Biotechnology (-2.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RPRX($18.4B) has a higher market cap than HALO($8.99B). RPRX has higher P/E ratio than HALO: RPRX (24.55) vs HALO (16.14). HALO YTD gains are higher at: 13.640 vs. RPRX (11.206). RPRX has higher annual earnings (EBITDA): 1.59B vs. HALO (845M). RPRX has more cash in the bank: 1.82B vs. HALO (702M). HALO has less debt than RPRX: HALO (1.51B) vs RPRX (8.95B). RPRX has higher revenues than HALO: RPRX (2.35B) vs HALO (1.24B).
HALORPRXHALO / RPRX
Capitalization8.99B18.4B49%
EBITDA845M1.59B53%
Gain YTD13.64011.206122%
P/E Ratio16.1424.5566%
Revenue1.24B2.35B53%
Total Cash702M1.82B39%
Total Debt1.51B8.95B17%
FUNDAMENTALS RATINGS
HALO vs RPRX: Fundamental Ratings
HALO
RPRX
OUTLOOK RATING
1..100
2124
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
2
Undervalued
PROFIT vs RISK RATING
1..100
4499
SMR RATING
1..100
1295
PRICE GROWTH RATING
1..100
4746
P/E GROWTH RATING
1..100
679
SEASONALITY SCORE
1..100
6564

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RPRX's Valuation (2) in the Pharmaceuticals Major industry is significantly better than the same rating for HALO (76) in the Biotechnology industry. This means that RPRX’s stock grew significantly faster than HALO’s over the last 12 months.

HALO's Profit vs Risk Rating (44) in the Biotechnology industry is somewhat better than the same rating for RPRX (99) in the Pharmaceuticals Major industry. This means that HALO’s stock grew somewhat faster than RPRX’s over the last 12 months.

HALO's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for RPRX (95) in the Pharmaceuticals Major industry. This means that HALO’s stock grew significantly faster than RPRX’s over the last 12 months.

RPRX's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as HALO (47) in the Biotechnology industry. This means that RPRX’s stock grew similarly to HALO’s over the last 12 months.

RPRX's P/E Growth Rating (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for HALO (67) in the Biotechnology industry. This means that RPRX’s stock grew somewhat faster than HALO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HALORPRX
RSI
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
58%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
57%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
45%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
47%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
48%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
48%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
51%
Declines
ODDS (%)
Bearish Trend 13 days ago
68%
Bearish Trend 16 days ago
60%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
50%
Bearish Trend 2 days ago
59%
Aroon
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
62%
View a ticker or compare two or three
Interact to see
Advertisement
HALO
Daily Signal:
Gain/Loss:
RPRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SDD10.980.02
+0.17%
ProShares UltraShort SmallCap600
GTO47.40N/A
N/A
Invesco Total Return Bond ETF
USDX25.52-0.01
-0.06%
SGI Enhanced Core ETF
BUFX21.33-0.02
-0.07%
FT Vest Laddered Enh & Mod Buffer ETF
DTEC45.12-1.75
-3.73%
ALPS Disruptive Technologies ETF

HALO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HALO has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if HALO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HALO
1D Price
Change %
HALO100%
+2.73%
AXON - HALO
47%
Loosely correlated
-1.89%
XENE - HALO
44%
Loosely correlated
+1.62%
IRON - HALO
39%
Loosely correlated
-1.17%
TECH - HALO
36%
Loosely correlated
-0.95%
IMCR - HALO
35%
Loosely correlated
-2.94%
More

RPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RPRX
1D Price
Change %
RPRX100%
+1.44%
AXON - RPRX
48%
Loosely correlated
-1.89%
IRON - RPRX
33%
Poorly correlated
-1.17%
MDGL - RPRX
31%
Poorly correlated
-1.49%
TECH - RPRX
31%
Poorly correlated
-0.95%
HALO - RPRX
31%
Poorly correlated
+2.73%
More